Of the 84, 35% had hormone receptor-positive/HER2-negative, 23% HER2-positive, and 43% triple negative breast cancers; 61% of tumors were MammaPrint high 2 (ultra-high risk), 30% stage T3 or T4, and 53% node-negative (Table 1). This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.